

Sorrento Therapeutics, Inc.  
Form 8-K  
April 07, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 1, 2011**

**SORRENTO THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**(State or other jurisdiction of incorporation)**

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K

**000-52228**  
(Commission File Number)

**33-0344842**  
(IRS Employer Identification No.)

**6042 Cornerstone Ct. West, Suite B**

**San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**(858) 210-3700**

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 1, 2011, Dr. Ernst-Guenter Afting, Dr. Antonius Schuh and Mr. Stephen Zaniboni resigned from their positions as directors of Sorrento Therapeutics, Inc., a Delaware corporation (the Company ), effective immediately, following the adoption of a resolution by a majority of the non-executive members of the Board of Directors of the Company (the Board ) to seek the resignation of Dr. Schuh as the Chief Executive Officer of the Company and to terminate Dr. Schuh's employment with the Company if he did not offer his resignation. Dr. Afting also resigned from his position as a member of the Audit Committee of the Board, Mr. Zaniboni also resigned from his position as a member of the Audit and Compensation Committees of the Board and Dr. Schuh also resigned from his position as Chairman of the Board.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SORRENTO THERAPEUTICS, INC.**

Date: April 7, 2011

By: /s/ Richard G. Vincent  
Name: Richard G. Vincent  
Title: Chief Financial Officer